Based on the guidelines published by the Health Authorities and depending on the study issue and on the proposed strategy, RCTs supports the pharmaceutical firms and medical device companies in choosing the type of assessment (cost-benefit analysis , cost-effectiveness analysis) and of model (Markov models, Discrete Event Simulation models, decision trees, etc.), whether by adapting an existing model or by creating a new one, in agreement with a Scientific Committee.
RCTs’ proposals are based on rigorous literature review and particular attention is paid to the mobilization of French data: INSEE data, use of French Claim Data base databases (DCIR, PMSI or EGB according to the study objectives ) for disease cost studies, but also for good use studies, or for data from an health-economic evaluation.
RCTs also supports the pharmaceutical firms and medical device companies in preparing the submission file to obtain an efficiency opinion from the Commission for Economic Evaluation and Public Health (CEESP).
Cost-benefit analysis on early vs. late knee prosthesis in French patients with gonarthrosis